Two new oral disease modifying therapies in relapsing remitting multiple sclerosis

被引：0
|
作者：
Lebrun, C. [1 ]
de Seze, J. [2 ]
机构：
[1] Hop Louis Pasteur, Serv Neurol, F-06002 Nice 1, France
[2] Hop Hautepierre, Serv Neurol, F-67000 Strasbourg, France
来源：
REVUE NEUROLOGIQUE | 2014年 / 170卷 / 12期
关键词：
PLACEBO-CONTROLLED PHASE-3; DOUBLE-BLIND; TERIFLUNOMIDE; TRIAL; BG-12;
D O I：
10.1016/j.neurol.2014.11.002
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：721 / 722
页数：2
相关论文
共 50 条
  • [1] Oral disease-modifying therapies for relapsing-remitting multiple sclerosis
    Thomas, Rachel Hutchins
    Wakefield, Richard A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (01) : 25 - 38
  • [2] Disease-modifying therapies in relapsing-remitting multiple sclerosis
    Gonzalez-Andrade, Fabricio
    Luis Alcaraz-Alvarez, Jose
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 365 - 373
  • [3] COST-UTILITY OF DISEASE MODIFYING THERAPIES FOR RELAPSING -REMITTING MULTIPLE SCLEROSIS
    Zimmermann, M.
    Brouwer, E.
    Tice, J. A.
    Seidner, M.
    Loos, A.
    Liu, S.
    Chapman, R. H.
    Kumar, V
    Carlson, J. J.
    VALUE IN HEALTH, 2017, 20 (05) : A193 - A193
  • [4] The efficacy and safety of oral disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review
    Shahtaheri, Rahil Sadat
    Nikfar, Shekoufeh
    Khorasani, Elahe
    Sabbagh-Baniazad, Mansoureh
    Goudarzi, Zahra
    Emamikhah, Maziar
    CURRENT JOURNAL OF NEUROLOGY, 2020, 19 (03): : 138 - 145
  • [5] Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: A systematic comparison
    Freedman, Mark S.
    Hughes, Bruce
    Mikol, Daniel D.
    Bennett, Randy
    Cuffel, Brian
    Divan, Vamil
    LaVallee, Nicole
    Al-Sabbagh, Ahmad
    EUROPEAN NEUROLOGY, 2008, 60 (01) : 1 - 11
  • [6] Pregnancy and disease-modifying therapies in patients with relapsing-remitting multiple sclerosis
    Oztekin, N. S.
    Oztekin, M. F.
    MULTIPLE SCLEROSIS, 2006, 12 : S95 - S96
  • [7] Disease modifying therapies for relapsing multiple sclerosis
    Wingerchuk, Dean M.
    Weinshenker, Brian G.
    BMJ-BRITISH MEDICAL JOURNAL, 2016, 354
  • [8] New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come
    Nicholas, J.
    Morgan-Followell, B.
    Pitt, D.
    Racke, M. K.
    Boster, A.
    JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE, 2012, 4 : 81 - 103
  • [9] THE COST-EFFECTIVENESS OF DISEASE MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Bozkaya, D.
    Livingston, T. P.
    Migliaccio-Walle, K.
    Mehta, S.
    Odom, T.
    VALUE IN HEALTH, 2015, 18 (03) : S283 - S283
  • [10] Disease modifying therapies discontinuation in relapsing-remitting Multiple Sclerosis: a monocentric cohort study
    Pasca, M.
    Forci, B.
    Mechi, C.
    Mariottini, A.
    Barilaro, A.
    Massacesi, L.
    Repice, A. M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 464 - 465
12345